Haemonetics ( (HAE) ) has released its Q1 earnings. Here is a breakdown of the information Haemonetics presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Haemonetics Corporation is a global medical technology company specializing in innovative healthcare solutions, including plasma collection technologies and hospital technologies aimed at enhancing patient outcomes. In its first quarter of fiscal 2026, Haemonetics reported a 4.4% decrease in revenue to $321.4 million, with a slight organic revenue increase of 0.5%. The company achieved a gross margin of 59.8%, up from 52.0% in the previous year, driven by pricing benefits and product mix improvements.
Key financial highlights include an adjusted earnings per diluted share of $1.10, a 7.8% increase from the prior year, and an adjusted operating income of $77.6 million, reflecting a 9.2% growth. Despite a decline in Plasma and Blood Center revenues, the Hospital segment showed a positive growth of 4.2%. The company also reported a free cash flow of $2 million, impacted by strategic investments and lower capital expenditures.
Haemonetics continues to focus on margin expansion and profitable growth, with significant advancements in Plasma and Hemostasis Management. The company is also taking steps to strengthen its commercial execution in Vascular Closure. The reaffirmation of its fiscal 2026 guidance underscores its confidence in achieving long-term strategic goals.
Looking ahead, Haemonetics remains committed to its growth strategy, with management optimistic about sustaining its market position and achieving its financial targets. The company aims to continue enhancing its product offerings and operational efficiencies to drive future success.